Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2006 2
2008 1
2009 2
2010 1
2011 3
2012 1
2013 1
2014 2
2015 3
2016 7
2017 6
2018 2
2019 5
2020 7
2021 8
2022 16
2023 12
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

73 results

Results by year

Filters applied: . Clear all
Page 1
Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer.
Forde PM, Spicer J, Lu S, Provencio M, Mitsudomi T, Awad MM, Felip E, Broderick SR, Brahmer JR, Swanson SJ, Kerr K, Wang C, Ciuleanu TE, Saylors GB, Tanaka F, Ito H, Chen KN, Liberman M, Vokes EE, Taube JM, Dorange C, Cai J, Fiore J, Jarkowski A, Balli D, Sausen M, Pandya D, Calvet CY, Girard N; CheckMate 816 Investigators. Forde PM, et al. N Engl J Med. 2022 May 26;386(21):1973-1985. doi: 10.1056/NEJMoa2202170. Epub 2022 Apr 11. N Engl J Med. 2022. PMID: 35403841 Free PMC article. Clinical Trial.
Neoadjuvant Targeted Therapy in Resectable NSCLC: Current and Future Perspectives.
Lee JM, McNamee CJ, Toloza E, Negrao MV, Lin J, Shum E, Cummings AL, Kris MG, Sepesi B, Bara I, Kurtsikidze N, Schulze K, Ngiam C, Chaft JE. Lee JM, et al. Among authors: shum e. J Thorac Oncol. 2023 Nov;18(11):1458-1477. doi: 10.1016/j.jtho.2023.07.006. Epub 2023 Jul 13. J Thorac Oncol. 2023. PMID: 37451404 Free PMC article. Review.
Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial.
Chaft JE, Oezkan F, Kris MG, Bunn PA, Wistuba II, Kwiatkowski DJ, Owen DH, Tang Y, Johnson BE, Lee JM, Lozanski G, Pietrzak M, Seweryn M, Byun WY, Schulze K, Nicholas A, Johnson A, Grindheim J, Hilz S, Shames DS, Rivard C, Toloza E, Haura EB, McNamee CJ, Patterson GA, Waqar SN, Rusch VW, Carbone DP; LCMC study investigators. Chaft JE, et al. Nat Med. 2022 Oct;28(10):2155-2161. doi: 10.1038/s41591-022-01962-5. Epub 2022 Sep 12. Nat Med. 2022. PMID: 36097216 Free PMC article. Clinical Trial.
TOP1 inhibition therapy protects against SARS-CoV-2-induced lethal inflammation.
Ho JSY, Mok BW, Campisi L, Jordan T, Yildiz S, Parameswaran S, Wayman JA, Gaudreault NN, Meekins DA, Indran SV, Morozov I, Trujillo JD, Fstkchyan YS, Rathnasinghe R, Zhu Z, Zheng S, Zhao N, White K, Ray-Jones H, Malysheva V, Thiecke MJ, Lau SY, Liu H, Zhang AJ, Lee AC, Liu WC, Jangra S, Escalera A, Aydillo T, Melo BS, Guccione E, Sebra R, Shum E, Bakker J, Kaufman DA, Moreira AL, Carossino M, Balasuriya UBR, Byun M, Albrecht RA, Schotsaert M, Garcia-Sastre A, Chanda SK, Miraldi ER, Jeyasekharan AD, TenOever BR, Spivakov M, Weirauch MT, Heinz S, Chen H, Benner C, Richt JA, Marazzi I. Ho JSY, et al. Among authors: shum e. Cell. 2021 May 13;184(10):2618-2632.e17. doi: 10.1016/j.cell.2021.03.051. Epub 2021 Mar 30. Cell. 2021. PMID: 33836156 Free PMC article.
Expanding the Role of Immunotherapy to Limited-Stage SCLC.
Punekar SR, Shum E. Punekar SR, et al. Among authors: shum e. J Thorac Oncol. 2020 Dec;15(12):1806-1808. doi: 10.1016/j.jtho.2020.09.021. J Thorac Oncol. 2020. PMID: 33246593 Free article. No abstract available.
Molecular cytology of the respiratory tract and pleura.
Zhou F, Shum E, Moreira AL. Zhou F, et al. Among authors: shum e. Cytopathology. 2022 Jan;33(1):14-22. doi: 10.1111/cyt.13045. Epub 2021 Aug 16. Cytopathology. 2022. PMID: 34333812 Review.
Baseline characteristics of participants in the Pre-Diabetes Interventions and Continued Tracking to Ease-out Diabetes (Pre-DICTED) Program.
Yeung KF, Lee YQ, Chong MFF, Gandhi M, Lam AYR, Julianty S, Tan GCS, Ho ETL, Goh SY, Tan GSW, Shum EJW, Finkelstein EA, Jafar TH, van Dam RM, Teoh YL, Thumboo J, Bee YM. Yeung KF, et al. Among authors: shum ejw. BMJ Open Diabetes Res Care. 2022 Oct;10(5):e002966. doi: 10.1136/bmjdrc-2022-002966. BMJ Open Diabetes Res Care. 2022. PMID: 36220198 Free PMC article. Clinical Trial.
In vivo metabolomics identifies CD38 as an emergent vulnerability in LKB1 -mutant lung cancer.
Deng J, Peng DH, Fenyo D, Yuan H, Lopez A, Levin DS, Meynardie M, Quinteros M, Ranieri M, Sahu S, Lau SCM, Shum E, Velcheti V, Punekar SR, Rekhtman N, Dowling CM, Weerasekara V, Xue Y, Ji H, Siu Y, Jones D, Hata AN, Shimamura T, Poirier JT, Rudin CM, Hattori T, Koide S, Papagiannakopoulos T, Neel BG, Bardeesy N, Wong KK. Deng J, et al. Among authors: shum e. bioRxiv [Preprint]. 2023 Apr 20:2023.04.18.537350. doi: 10.1101/2023.04.18.537350. bioRxiv. 2023. PMID: 37131623 Free PMC article. Preprint.
The Evolving Role of Biomarkers in Personalized Lung Cancer Therapy.
Sharma J, Shum E, Chau V, Paucar D, Cheng H, Halmos B. Sharma J, et al. Among authors: shum e. Respiration. 2017;93(1):1-14. doi: 10.1159/000453086. Epub 2016 Nov 29. Respiration. 2017. PMID: 27894113 Free article. Review. No abstract available.
73 results